FDA Accepts Supplement Application for VANFLYTA by Daiichi Sankyo
The FDA has accepted a supplemental application for VANFLYTA (quizartinib dihydrochloride) from Daiichi Sankyo.
Asset / Drug
Drug and asset intelligence for VANFLYTA with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
FLT3 Inhibitor
No catalysts indexed for this entity yet.
July 8, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.